NCT04189250

Brief Summary

The aim of this study is the comparison of two measurement protocols determining hemoglobin mass with two different blood sampling strategies.Both protocols are based on the principle of the carbonmonoxid (CO) rebreathing method. During this measurement, CO is inhaled for a specific time period by the subject in a closed circuit and it is used as a marker to tag circulating hemoglobin.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
31

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 3, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 6, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

January 20, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 20, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2020

Completed
Last Updated

March 11, 2020

Status Verified

March 1, 2020

Enrollment Period

3 months

First QC Date

December 3, 2019

Last Update Submit

March 9, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Comparison of two CO rebreathing protocols (aCO and oCO)

    The aim is to assess the confidence interval of aCO with a ten min rebreathing period in supine position compared to oCO with a two min seated rebreathing period. The mean difference in hemoglobin mass will be determined, using the aCO and oCO.

    During data collection (3 months)

  • Comparison of capillary and venous bloodsampling

    The aim is to compare capillary and venous blood samples collected simultaneously during aCO. The goal is to determine, if the site of blood sampling alters the measured carboxy-hemoglobin and hence the calculated hemoglobin mass. The outcome will be the confidence interval of mean difference measured with capillary and venous blood sampling.

    During data collection (3 months)

Secondary Outcomes (1)

  • Reliability of aCO and oCO

    During data collection (3 months)

Study Arms (2)

Optimized carbonmonoxid rebreathing protocol (oCO)

PLACEBO COMPARATOR

2 min rebreathing period seated position capillary blood sampling

Device: Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments

Automatized carbonmonoxide rebreathing protocol (aCO)

ACTIVE COMPARATOR

10 minutes rebreathing period supine position venous blood sampling

Device: Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments

Interventions

The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.

Automatized carbonmonoxide rebreathing protocol (aCO)Optimized carbonmonoxid rebreathing protocol (oCO)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 18 or higher
  • healthy (self-reported)
  • women and men

You may not qualify if:

  • smoker
  • implementation of high altitude training six weeks before and during the study
  • sickness before and during the study
  • blood donation 6 weeks before and during the study
  • pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Swiss Federal Instistiution of Sport

Magglingen, Switzerland

RECRUITING

Related Publications (4)

  • Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total haemoglobin mass routinely. Eur J Appl Physiol. 2005 Dec;95(5-6):486-95. doi: 10.1007/s00421-005-0050-3. Epub 2005 Oct 13.

    PMID: 16222540BACKGROUND
  • Fagoni N, Breenfeldt Andersen A, Oberholzer L, Haider T, Meinild Lundby AK, Lundby C. Reliability and validity of non-invasive determined haemoglobin mass and blood volumes. Clin Physiol Funct Imaging. 2018 Mar;38(2):240-245. doi: 10.1111/cpf.12406. Epub 2017 Jan 30.

    PMID: 28135764BACKGROUND
  • Siebenmann C, Keiser S, Robach P, Lundby C. CORP: The assessment of total hemoglobin mass by carbon monoxide rebreathing. J Appl Physiol (1985). 2017 Sep 1;123(3):645-654. doi: 10.1152/japplphysiol.00185.2017. Epub 2017 Jun 29.

    PMID: 28663373BACKGROUND
  • Steiner T, Wehrlin JP. Comparability of haemoglobin mass measured with different carbon monoxide-based rebreathing procedures and calculations. Scand J Clin Lab Invest. 2011 Feb;71(1):19-29. doi: 10.3109/00365513.2010.534174. Epub 2010 Nov 23.

    PMID: 21091271BACKGROUND

Study Officials

  • Jon Wehrlin, Dr. scient., MSc.

    Swiss Federal Institute of Sport Magglingen

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jon Wehrlin, Dr. scient., MSc.

CONTACT

Katja Kellenberger, MSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2019

First Posted

December 6, 2019

Study Start

January 20, 2020

Primary Completion

April 20, 2020

Study Completion

August 1, 2020

Last Updated

March 11, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Locations